SEC Form 4 · accession 0000884731-17-000004
ARIAD PHARMACEUTICALS INC · ARIA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paris Panayiotopoulos
Officer — President and CEO · Director
Period of report
Jan 13, 2017
Accepted (ET)
Jan 17, 2017 · 5:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000884731
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 13, 2017 | M | 66,600 | $0.00 | A | 192,678 | D | |
| Common StockF3 | Jan 17, 2017 | F | 33,300 | $23.6917 | D | 159,378 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4,F5 | $0.00 | Jan 13, 2017 | M | 66,600 | D | — | — | Common Stock | 66,600 | 66,800 | D |
Explanation of responses
- F1Shares were acquired upon the vesting of a Restricted Stock Unit previously granted on January 13, 2016.
- F2Represents shares sold to satisfy withholding tax requirements pursuant to a Rule 10b5-1 trading plan adopted June 15, 2016.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.67 to $23.72, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer,or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
- F4This RSU vests as to approximately one third of the award on each of July 13, 2016, January 13, 2017 and July 13, 2017.
- F5N/A